Tahir Effendi, MD
Internal Medicine · Watervliet, NYNPI 1285739789
Payments from drug & device makers
Across 355 payments — averaging $135.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Renalytix AI, Inc.$43K
- GSK$1K
- Novo Nordisk$821
- Johnson & Johnson$509
- AbbVie$448
- AstraZeneca$413
- plus $2K from 30 others
What the payments were for
- Consulting fees$10,88067%
- Food & beverage$5,29233%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Renalytix AI, Inc. | 22 | $42,974 |
| GSK | 60 | $1,014 |
| Novo Nordisk | 40 | $821 |
| Johnson & Johnson | 79 | $509 |
| AbbVie(2 entities) | 24 | $448 |
| AstraZeneca | 27 | $413 |
| Dexcom, Inc. | 12 | $242 |
| Lilly USA, LLC | 10 | $235 |
| Abbott | 10 | $184 |
| Bayer | 7 | $144 |
| Amgen | 7 | $137 |
| Novartis | 7 | $128 |
| Boehringer Ingelheim | 5 | $96 |
| Astellas Pharma US Inc | 4 | $89 |
| Pfizer | 5 | $82 |
| Axsome Therapeutics, Inc. | 3 | $73 |
| Sanofi-aventis U.S. LLC | 4 | $49 |
| Mannkind Corporation | 4 | $48 |
| Exact Sciences | 2 | $47 |
| Phathom Pharmaceuticals, Inc. | 2 | $45 |
| Merck | 3 | $37 |
| Amneal Pharmaceuticals LLC | 2 | $32 |
| Xeris Pharmaceuticals, Inc. | 2 | $28 |
| Sanofi Pasteur Inc. | 1 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Seqirus USA Inc | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Vertex | 1 | $14 |
| BD | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Medtronic | 1 | $13 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$48,098 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 126 | $197,017 |
| JardianceEmpagliflozin | 135 | $176,067 |
| FarxigaDapagliflozin Propanediol | 137 | $151,258 |
| TrulicityDulaglutide | 87 | $131,332 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $47,635 |
| RybelsusSemaglutide | 20 | $35,632 |
| TradjentaLinagliptin | 37 | $33,227 |
| EliquisApixaban | 32 | $31,096 |
| JanuviaSitagliptin Phosphate | 21 | $30,265 |
| MounjaroTirzepatide | 11 | $19,814 |
| InvokanaCanagliflozin | 14 | $17,477 |
| XareltoRivaroxaban | 14 | $14,083 |
| MyrbetriqMirabegron | 13 | $8,195 |
| DapagliflozinDapagliflozin Propanediol | 14 | $8,136 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $6,682 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $821 | $232,649146 claims |
| Boehringer IngelheimJardiance, Tradjenta | $96 | $209,294172 claims |
| AstraZenecaFarxiga | $413 | $151,258137 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $235 | $151,14698 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,014 | $54,31789 claims |
| Johnson & JohnsonInvokana, Xarelto | $509 | $31,55928 claims |
| PfizerEliquis | $82 | $31,09632 claims |
| MerckJanuvia | $37 | $30,26521 claims |
| Astellas Pharma US IncMyrbetriq | $89 | $8,19513 claims |
| AbbVieSynthroid | $448 | $3,47431 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $32 | $2,934278 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Watervliet
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.